Benlysta

Benlysta

belimumab

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Belimumab
Indications/Uses
Reducing disease activity in adults w/ active autoAb +ve SLE receiving standard therapy. Active lupus nephritis in adults in combination w/ background immunosuppressive therapies.
Dosage/Direction for Use
Adult SLE & lupus nephritis 10 mg/kg IV infusion over 1 hr on days 0, 14 & 28 & at 4-wk intervals thereafter. Patient w/ allergies Premed w/ oral antihistamine w/ or w/o antipyretic before infusion.
Contraindications
Special Precautions
Not to be inj as IV push or bolus. Discontinue use if progressive multifocal leukoencephalopathy is confirmed. Not recommended in severe active CNS lupus. History of multiple drug allergies or significant hypersensitivity. Increased risk of infections & malignancies. Psychiatric disorders eg, depression, suicidal ideation & behaviour. Avoid immunisation 30 days before & during therapy. Concomitant use w/ other B-cell targeted therapy. Renal & hepatic impairment. Women of childbearing potential should use adequate contraception during & at least 4 mth after treatment. Pregnancy & lactation. Not recommended to be used in childn & adolescents w/ active lupus nephritis. Childn <18 yr. Not recommended in elderly.
Adverse Reactions
Infections. Hypersensitivity reaction; depression; pyrexia, infusion-related reaction.
MIMS Class
Immunosuppressants
ATC Classification
L04AG04 - belimumab ; Belongs to the class of monoclonal antibodies. Used as immunosuppressants.
Presentation/Packing
Form
Benlysta powd for infusion (vial) 120 mg
Packing/Price
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in